Prevenar maintains lead in pneumococcal vaccine mkt
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.08.12 05:57:28
가나다라
0
Vaxneuvance enters market upon its launch in April...goes head-to-head with established powerhouse Prevenar1 3
Prevenar 13’s pediatric market share in Q2 reaches 76.7%, adult market 81.3%
MSD preemptively targets the pediatric NIP market... but struggles to expand its share in the non-reimbursed adult market
The pneumococcal vaccine market, dominated by Pfizer's Prevenar 13, is now facing competition with the introduction of MSD's Vaxneuvance.
The Q2 share report, which is the first report issued after Vaxneuvance’s introduction in April, showed that while Pfizer's Prevenar 13 sales remained strong, Vaxneuvance gained a larger share of the non-reimbursed adult pneumococcal vaccine market.
▲(from the left)Pic of Prevenar 13, Vaxneuvance
Prevenar 13 was the dominant pneumococcal vaccine in Korea’s market prior to the introduction of Vaxneuvance. It generated KRW 45.8 billion in sales last year (IQVIA data), and the drug occupied 98.9% in March 98.9% among children and 100% among adults (UBIST data).
However, since t
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)